Search Results 271-280 of 18472 for Relapse

  1. A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell ...

  2. Nicotine Dependence Center - Overview - Mayo Clinic

    ... relapse prevention strategies. The Mayo Clinic Nicotine Dependence Center at Mayo Clinic's campus in Minnesota was one of the first centers in the United ...

  3. Relapsed or High-Risk Myeloma Receiving Novel Immunotherapies Outcomes of Patients - Mayo Clinic

    immunotherapy and to assess selection differences, treatment sequencing and outcomes from salvage therapy after first or subsequent novel immunotherapy.

  4. Alcoholic Liver Disease Clinical Trials - Mayo Clinic Research

    The primary aim of this study is to define a comprehensive digital phenotype that predicts risk for near-future relapse or relapse in alcohol use in patients ...

  5. A Study to Evaluate CTX110 in Subjects with Relapsed or Refractory B-Cell Malignancies - Mayo Clinic

    The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies. Participation ...

  6. A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma - Mayo Clinic

    A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma · Overview · Participation eligibility · Participating Mayo Clinic locations.

  7. GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma. Print details. Share; Facebook · Twitter. Overview ...

  8. A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia - Mayo Clinic

    A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared with Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients with Relapsed or ...

  9. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  10. Hematology - Clinical trials

    ... relapsed acute leukemia (AML or ALL) for future biological studies. By accruing samples both at initial diagnosis and at relapse, we will be able to ...